- Home
- MRSN vs BNR Comparison
MRSN vs BNR Comparison
Compare MRSN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- BNR
- Stock Information
- Founded
- MRSN 2001
- BNR 2014
- Country
- MRSN United States
- BNR China
- Employees
- MRSN N/A
- BNR N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- MRSN Health Care
- BNR Health Care
- Exchange
- MRSN Nasdaq
- BNR Nasdaq
- Market Cap
- MRSN 71.9M
- BNR 61.7M
- IPO Year
- MRSN 2017
- BNR 2020
- Fundamental
- Price
- MRSN $0.48
- BNR $5.10
- Analyst Decision
- MRSN Buy
- BNR
- Analyst Count
- MRSN 4
- BNR 0
- Target Price
- MRSN $4.33
- BNR N/A
- AVG Volume (30 Days)
- MRSN 3.8M
- BNR 5.3K
- Earning Date
- MRSN 03-03-2025
- BNR 03-27-2025
- Dividend Yield
- MRSN N/A
- BNR N/A
- EPS Growth
- MRSN N/A
- BNR N/A
- EPS
- MRSN N/A
- BNR N/A
- Revenue
- MRSN $40,497,000.00
- BNR $72,832,704.00
- Revenue This Year
- MRSN N/A
- BNR $52.90
- Revenue Next Year
- MRSN $67.68
- BNR $48.35
- P/E Ratio
- MRSN N/A
- BNR N/A
- Revenue Growth
- MRSN 9.88
- BNR N/A
- 52 Week Low
- MRSN $0.45
- BNR $2.62
- 52 Week High
- MRSN $5.96
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- MRSN 35.88
- BNR 36.80
- Support Level
- MRSN $0.49
- BNR $4.90
- Resistance Level
- MRSN $0.56
- BNR $5.76
- Average True Range (ATR)
- MRSN 0.05
- BNR 0.49
- MACD
- MRSN 0.02
- BNR -0.17
- Stochastic Oscillator
- MRSN 28.11
- BNR 19.77
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.